SCHEMBL4398463

SCHEMBL4398463

CCN1C(=O)N(c2c(F)ccc(O)c2F)Cc2cnc(NC3CCC(O)CC3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.42
FGFR4 P22455 10/20 0.41
CDK4 P11802 2/20 0.39
CCND1 P24385 2/20 0.39
CCND2 P30279 1/20 0.39
CCND3 P30281 1/20 0.39
MAPK8 P45983 3/20 0.38
MAPK9 P45984 3/20 0.38
FGFR1 P11362 2/20 0.38
MAPK10 P53779 2/20 0.38
TNK2 Q07912 2/20 0.37
MAP4K2 Q12851 2/20 0.37
EGFR P00533 1/20 0.36
FYN P06241 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
PRKACA P17612 1/20 0.36
FGFR2 P21802 1/20 0.36
FGFR3 P22607 1/20 0.36
PRKACG P22612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4551241 0.92 FGFR4 (0.40) MAPK14FGFR4CDK4CCND1CCND2
SCHEMBL4406449 0.91 FGFR4 (0.39) FGFR4CDK4CCND1CCND2CCND3
SCHEMBL4411078 0.89 FGFR4 (0.44) MAPK14FGFR4CDK4CCND1MAPK8
SCHEMBL4410276 0.89 FGFR4 (0.49) MAPK14FGFR4CDK4CCND1FGFR1
SCHEMBL4399032 0.86 MAPK14 (0.43) MAPK14FGFR4CDK4CCND1CCND2
SCHEMBL4405515 0.86 FGFR1 (0.45) MAPK14FGFR4MAPK8MAPK9FGFR1
SCHEMBL4410526 0.85 FGFR4 (0.47) MAPK14FGFR4FGFR1FGFR2FGFR3
SCHEMBL4398707 0.85 FGFR4 (0.54) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL4406062 0.85 FGFR4 (0.43) MAPK14FGFR4MAPK8MAPK9FGFR1
SCHEMBL4411835 0.84 MAPK14 (0.44) MAPK14FGFR4FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 MAPK14 229/4885FGFR4 191/4885CDK4 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.